These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2044569)

  • 1. Imaging pattern of radiolabelled lymphokine-activated killer cells in patients with metastatic malignant melanoma.
    Schäfer E; Dummer R; Eilles C; Börner W; Martin R; Rendl J; Burg G
    Eur J Nucl Med; 1991; 18(2):106-10. PubMed ID: 2044569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional administration of lymphokine-activated killer cells can be superior to intravenous application.
    Keilholz U; Schlag P; Tilgen W; Brado B; Galm F; Görich J; Kauffmann GW; Möller P; Schneider S; Hunstein W
    Cancer; 1992 Apr; 69(8):2172-5. PubMed ID: 1544123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of lymphokine-activated killer cells with or without radiation therapy against malignant brain tumors.
    Nakagawa K; Kamezaki T; Shibata Y; Tsunoda T; Meguro K; Nose T
    Neurol Med Chir (Tokyo); 1995 Jan; 35(1):22-7. PubMed ID: 7700478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2].
    Nakano E; Iwasaki A; Seguchi T; Sugao H; Tada Y; Matsuda M; Sonoda T
    Nihon Hinyokika Gakkai Zasshi; 1991 Mar; 82(3):395-404. PubMed ID: 2072602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases.
    Keilholz U; Scheibenbogen C; Brado M; Georgi P; Maclachlan D; Brado B; Hunstein W
    Eur J Cancer; 1994; 30A(1):103-5. PubMed ID: 8142149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The in vivo distribution of murine lymphokine activated killer cells in splenectomized host.
    Chao TY; Chu TM
    Proc Natl Sci Counc Repub China B; 1990 Dec; 14(4):223-7. PubMed ID: 2101449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study of adoptive immunotherapy for metastatic renal cell carcinoma with lymphokine-activated killer (LAK) cells and interleukin-2. II. Clinical evaluation].
    Nomura K; Fujioka T
    Nihon Hinyokika Gakkai Zasshi; 1993 May; 84(5):831-40. PubMed ID: 8320888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scintigraphy with In-111 labeled lymphokine-activated killer cells of malignant brain tumor.
    Itoh K; Sawamura Y; Hosokawa M; Kobayashi H
    Radiat Med; 1988; 6(6):276-81. PubMed ID: 2854899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
    J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cells migrate to tumour sites after extracorporeal interleukin 2 stimulation and reinfusion in a patient with metastatic melanoma.
    Dummer R; Becker JC; Eilles C; Schäfer E; Börner W; Burg G
    Br J Dermatol; 1993 Apr; 128(4):399-403. PubMed ID: 8494752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue distribution and tumor localization of effector cells in adoptive immunotherapy of cancer.
    Basse PH
    APMIS Suppl; 1995; 55():1-28. PubMed ID: 8534522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of lymphokine-activated killer cells and interleukin-2 in treating metastatic renal cell carcinoma.
    Fujioka T; Nomura K; Hasegawa M; Ishikura K; Kubo T
    Br J Urol; 1994 Jan; 73(1):23-31. PubMed ID: 8298895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
    Kimoto Y
    Hum Cell; 1992 Sep; 5(3):226-35. PubMed ID: 1467321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biodistribution of lymphokine-activated killer (LAK) cells in Wag rats after hepatic-artery or jugular-vein infusion.
    Kuppen PJ; Marinelli A; Camps JA; Pauwels EK; van de Velde CJ; Fleuren GJ; Eggermont AM
    Int J Cancer; 1992 Sep; 52(2):266-70. PubMed ID: 1521913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study of adoptive immunotherapy with lymphokine-activated killer (LAK) cells and interleukin-2 for metastatic renal cell carcinoma. I. Generation of LAK cells by incubation in serum-free medium].
    Nomura K; Fujioka T
    Nihon Hinyokika Gakkai Zasshi; 1993 May; 84(5):822-30. PubMed ID: 8320887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging pattern of previously in vitro sensitized and interleukin-2 expanded autologous lymphocytes in human cancer.
    Mukherji B; Arnbjarnarson O; Spitznagle LA; Kalish RI; Hoffman J; Ergin MT; Spencer RP
    Int J Rad Appl Instrum B; 1988; 15(4):419-27. PubMed ID: 3267147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lymphokine-activated killer (LAK) therapy for metastatic renal cell carcinoma].
    Nakano E
    Hinyokika Kiyo; 1992 Nov; 38(11):1305-9. PubMed ID: 1485586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysis of allogeneic and autologous melanoma cells by IL-7-induced lymphokine-activated killer cells.
    Böhm M; Möller P; Kalbfleisch U; Worm M; Czarnetzki BM; Schadendorf D
    Br J Cancer; 1994 Jul; 70(1):54-9. PubMed ID: 8018541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor.
    Teichmann JV; Ludwig WD; Thiel E
    Leuk Res; 1992; 16(3):287-98. PubMed ID: 1560676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.